A Small Human Marijuana Study Found Respiratory-Response Tolerance but a Non-Significant Pulse Trend

A 1976 study of eight healthy men found adaptation in a carbon-dioxide respiratory-response measure during prolonged marijuana access. Pulse elevation also became smaller across sessions, but that change was not statistically significant.

The respiratory outcome was a response curve

The investigators measured responses to carbon dioxide before and after controlled smoking sessions during a longer exposure study. This is a specific physiological assessment, not a comprehensive evaluation of lung injury, everyday breathing or respiratory safety.

The two adaptation claims had different support

A significant change in the respiratory time-effect curve supported tolerance on that measure. The pulse trend did not reach statistical significance. Similar directions across outcomes should not be reported as two equally demonstrated tolerance findings.

The study population and protocol were narrow

The sample comprised eight healthy male participants, assessed at several stages of the longer study after refraining from use since the previous evening. The small, selected group and historical preparation limit generalization to other patients, routes or exposure patterns.

Interpreting the evidence

This experiment illustrates why each endpoint retains its own statistical conclusion. It does not establish freedom from respiratory harm, protection from other depressant drugs or a personal fitness judgment. An exposure-associated physiological adaptation is narrower than a general safety finding.

Related reading: interpreting cannabis tolerance claims.

Research reference

Bellville JW; Gasser JC; Miyake T; Aqleh K (1976). Tolerance to the respiratory effects of marijuana in man. The Journal of pharmacology and experimental therapeutics. PubMed research record.

This analysis draws on the supplied abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

APD371 Maintained a Pain-Response Effect for Five Days in a Preclinical Development Study

A 2017 drug-discovery report described APD371, a selective CB2 agonist, maintaining its effect during a five-day rat osteoarthritis-pain protocol. That short preclinical finding is different from established long-term clinical efficacy. The report concerned selection of a development candidate The authors considered receptor efficacy, pharmacokinetics and pharmaceutical properties alongside an oral…

Spread the love

Read Article: APD371 Maintained a Pain-Response Effect for Five Days in a Preclinical Development Study

Two Biased CB2 Agonists Had Different Durability in a Rat Osteoarthritis Experiment

A 2021 rat study found sustained pain-response effects with JWH133 while another CB2 agonist lost efficacy after two days under its repeated-treatment protocol. Shared receptor targeting did not establish equal durability. The compounds were compared in a defined model The experiment used chemically induced osteoarthritis and measured pressure responses and…

Spread the love

Read Article: Two Biased CB2 Agonists Had Different Durability in a Rat Osteoarthritis Experiment

An Acute Cannabis Review Treated Neurocognitive Response as a Multi-Factor Question

A 2021 review argued that acute neurocognitive responses to cannabis vary with biological, pharmacological and exposure-related factors. A product label or use-frequency category alone cannot capture all the determinants discussed. The review considered interacting sources of variation It discussed brain-network activity, formulation, use frequency and differences between therapeutic and recreational…

Spread the love

Read Article: An Acute Cannabis Review Treated Neurocognitive Response as a Multi-Factor Question

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us